John Chalmers
Direktor/Vorstandsmitglied bei Prognomix, Inc.
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Pavel Hamet | M | - |
Prognomix, Inc.
 Prognomix, Inc. Pharmaceuticals: GenericHealth Technology Prognomix, Inc. develops market molecular diagnostic kits for testing of diabetes complications. Its products include PGX IR01, PGx GR01, PGx CD01 and PGx IR02. The firm focuses on discovery and clinical application of genomic signatures predictive of susceptibility to diseases, their complications and individual therapeutic responsiveness. The company was founded by Johanne Tremblay and Pavel Hamet in 2005 and is headquartered in Montreal, Canada. | 19 Jahre |
| Johanne Tremblay | M | - |
Prognomix, Inc.
Prognomix, Inc. Pharmaceuticals: GenericHealth Technology Prognomix, Inc. develops market molecular diagnostic kits for testing of diabetes complications. Its products include PGX IR01, PGx GR01, PGx CD01 and PGx IR02. The firm focuses on discovery and clinical application of genomic signatures predictive of susceptibility to diseases, their complications and individual therapeutic responsiveness. The company was founded by Johanne Tremblay and Pavel Hamet in 2005 and is headquartered in Montreal, Canada. | - |
| Marc-André Blais | M | - |
Prognomix, Inc.
Prognomix, Inc. Pharmaceuticals: GenericHealth Technology Prognomix, Inc. develops market molecular diagnostic kits for testing of diabetes complications. Its products include PGX IR01, PGx GR01, PGx CD01 and PGx IR02. The firm focuses on discovery and clinical application of genomic signatures predictive of susceptibility to diseases, their complications and individual therapeutic responsiveness. The company was founded by Johanne Tremblay and Pavel Hamet in 2005 and is headquartered in Montreal, Canada. | - |
| Francesco Bellini | M | 77 |
Prognomix, Inc.
Prognomix, Inc. Pharmaceuticals: GenericHealth Technology Prognomix, Inc. develops market molecular diagnostic kits for testing of diabetes complications. Its products include PGX IR01, PGx GR01, PGx CD01 and PGx IR02. The firm focuses on discovery and clinical application of genomic signatures predictive of susceptibility to diseases, their complications and individual therapeutic responsiveness. The company was founded by Johanne Tremblay and Pavel Hamet in 2005 and is headquartered in Montreal, Canada. | - |
| Normand Balthazard | M | - |
Prognomix, Inc.
Prognomix, Inc. Pharmaceuticals: GenericHealth Technology Prognomix, Inc. develops market molecular diagnostic kits for testing of diabetes complications. Its products include PGX IR01, PGx GR01, PGx CD01 and PGx IR02. The firm focuses on discovery and clinical application of genomic signatures predictive of susceptibility to diseases, their complications and individual therapeutic responsiveness. The company was founded by Johanne Tremblay and Pavel Hamet in 2005 and is headquartered in Montreal, Canada. | - |
| Lynda Desroches | F | - |
Prognomix, Inc.
Prognomix, Inc. Pharmaceuticals: GenericHealth Technology Prognomix, Inc. develops market molecular diagnostic kits for testing of diabetes complications. Its products include PGX IR01, PGx GR01, PGx CD01 and PGx IR02. The firm focuses on discovery and clinical application of genomic signatures predictive of susceptibility to diseases, their complications and individual therapeutic responsiveness. The company was founded by Johanne Tremblay and Pavel Hamet in 2005 and is headquartered in Montreal, Canada. | - |
| Stephen Harrap | M | - |
Prognomix, Inc.
Prognomix, Inc. Pharmaceuticals: GenericHealth Technology Prognomix, Inc. develops market molecular diagnostic kits for testing of diabetes complications. Its products include PGX IR01, PGx GR01, PGx CD01 and PGx IR02. The firm focuses on discovery and clinical application of genomic signatures predictive of susceptibility to diseases, their complications and individual therapeutic responsiveness. The company was founded by Johanne Tremblay and Pavel Hamet in 2005 and is headquartered in Montreal, Canada. | - |
| Michel Marre | M | - |
Prognomix, Inc.
Prognomix, Inc. Pharmaceuticals: GenericHealth Technology Prognomix, Inc. develops market molecular diagnostic kits for testing of diabetes complications. Its products include PGX IR01, PGx GR01, PGx CD01 and PGx IR02. The firm focuses on discovery and clinical application of genomic signatures predictive of susceptibility to diseases, their complications and individual therapeutic responsiveness. The company was founded by Johanne Tremblay and Pavel Hamet in 2005 and is headquartered in Montreal, Canada. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Barry Eldridge | M | 77 |
The University of Sydney
| 4 Jahre |
| Chee Liew Yao | M | 85 |
The University of Sydney
| 4 Jahre |
| Frederick Arthur Finch | M | 77 |
The University of New South Wales
| 4 Jahre |
| Malcolm John Castle | M | - |
The University of New South Wales
| 4 Jahre |
| Fook Ngian Yoong | M | 82 |
The University of Sydney
| 4 Jahre |
| Say Sin Chua | M | 77 |
The University of New South Wales
| 4 Jahre |
| Khairuddin bin Mohamed Yusof | M | 81 |
The University of Sydney
| 3 Jahre |
| Yuet Yun Kan | M | 84 |
The University of Sydney
| 4 Jahre |
| Carlisle Procter | M | 83 |
The University of Sydney
| 4 Jahre |
| Frederick Kempson | M | 81 |
The University of New South Wales
| 4 Jahre |
| David Edward Wills | M | 76 |
The University of New South Wales
| 4 Jahre |
| Lisjanto Tjiptobiantoro | M | 75 |
The University of New South Wales
| 4 Jahre |
| David Michael Spratt | M | 79 |
The University of New South Wales
| 4 Jahre |
| Bow Tan Mah | M | - |
The University of New South Wales
| 4 Jahre |
| Colin Randall | M | - |
The University of New South Wales
| 4 Jahre |
| Philip Cox | M | 84 |
The University of Sydney
| 4 Jahre |
| Barbara Jane Barron | M | - |
The University of Sydney
| 34 Jahre |
| John Winston Howard | M | 85 |
The University of Sydney
| 3 Jahre |
| Bill Beerworth | M | - |
The University of Sydney
| 5 Jahre |
| Phillip Lloyd Harry | M | - |
The University of Sydney
| 4 Jahre |
| Wallace MacArthur King | M | 79 |
The University of New South Wales
| 1 Jahre |
| Arthur Dew | M | 82 |
The University of Sydney
| 4 Jahre |
| Heng Nee Eng | M | 78 |
The University of New South Wales
| 4 Jahre |
| Eng Soon Tan | M | 75 |
The University of New South Wales
| 4 Jahre |
| Fong Fui Wong | M | 80 |
The University of New South Wales
| 4 Jahre |
| Peter Sullivan | M | 76 |
The University of New South Wales
| 4 Jahre |
| Paul Salteri | M | - |
The University of New South Wales
| 4 Jahre |
| Greg Hancock | M | 65 |
The University of New South Wales
| 4 Jahre |
| R. John Anderson | M | 73 |
The University of New South Wales
| 4 Jahre |
| Vic Wall | M | - |
The University of Sydney
| 4 Jahre |
| Christopher H. Young | M | - |
The University of Sydney
| 4 Jahre |
| David Zalmon Baffsky | M | 83 |
The University of Sydney
| 3 Jahre |
| Robert Ainslie Yeates | M | - |
The University of New South Wales
| 4 Jahre |
| Trevor Moore | M | - |
The University of Sydney
| 4 Jahre |
| Greg Laurie | M | 81 |
The University of New South Wales
| - |
| Abdul Aziz bin Abdul Rahman | M | 78 |
The University of New South Wales
| 4 Jahre |
| Geoff Jordan | M | - |
The University of New South Wales
| 4 Jahre |
| Khee Seong Leong | M | 85 |
The University of New South Wales
| - |
| Khamsouk Sundara | M | 79 |
The University of New South Wales
| 4 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Australien | 23 | 48,94% |
| Japan | 16 | 34,04% |
| Kanada | 8 | 17,02% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- John Chalmers
- Persönliches Netzwerk
